GlassScriptPhysician profile
Benjamin J Nichols
NPI 1790983237
$6,114.73
in general payments reported to CMS, 2019-2025
25 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $92.34 · 2021: $235 · 2022: $559 · 2023: $1,467 · 2024: $1,727 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,798 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,797.53 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $844.08 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $680.36 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Abbvie INC. | $656.84 | 2019-2025 | |
| Lilly USA, LLC | $536.91 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $460.63 | 2022-2025 | Otezla |
| Merz North America, INC. | $310.26 | 2019-2025 | Xeomin |
| Leo Pharma INC. | $280.53 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $272.49 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $266.96 | 2020-2025 | Nemluvio |
| Ucb, INC. | $265.90 | 2024-2025 | Bimzelx |
| Pfizer INC. | $256.85 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $249.60 | 2019-2025 | |
| Revance Therapeutics, INC. | $193.36 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $163.64 | 2019-2023 | Jublia |
| Biofrontera INC. | $142.68 | 2019-2025 | Ameluz, Rhodoled Xl, Xepi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $138.26 | 2024-2025 | Zoryve |
| Genzyme Corporation | $111.01 | 2023-2025 | |
| Organon LLC | $67.92 | 2025 | Vtama |
| Allergan, INC. | $62.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.26 | 2024 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $36.70 | 2019 | |
| Thea Pharma INC. | $22.16 | 2023 | Iyuzeh |
| Strata Skin Sciences, INC. | $20.86 | 2019 | |
| Dermavant Sciences, INC. | $18.77 | 2023 | Vtama |
| Mission Pharmacal Company | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.